Boston Scientific Derivatives, gross, liabilities decreased by 6.3% to $1.33B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 22.1%, from $1.09B to $1.33B. Over 4 years (FY 2020 to FY 2024), Derivatives, gross, liabilities shows a downward trend with a -5.9% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase in liabilities suggests that market movements are moving against the company's hedge positions, potentially requiring future cash settlements.
This represents the aggregate fair market value of all derivative financial instruments that are in a liability position...
Standard for energy companies using derivatives to manage fuel and power price risk.
other_derivative_fair_value_of_derivative_liability| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.16B | $1.12B | $1.07B | $1.07B | $966.00M | $942.00M | $1.01B | $1.01B | $1.02B | $977.00M | $1.05B | $986.00M | $974.00M | $1.09B | $990.00M | $1.05B | $1.42B | $1.33B |
| QoQ Change | — | -3.7% | -4.4% | -0.4% | -9.5% | -2.5% | +6.7% | +0.4% | +1.2% | -4.3% | +7.5% | -6.1% | -1.2% | +11.6% | -8.9% | +5.8% | +35.2% | -6.3% |
| YoY Change | — | — | — | — | -16.9% | -15.9% | -6.2% | -5.4% | +5.7% | +3.7% | +4.5% | -2.3% | -4.6% | +11.3% | -5.7% | +6.2% | +45.4% | +22.1% |